ARISTOTLE Trial

Summary: Evaluated apixaban versus warfarin in patients with atrial fibrillation or flutter. Apixaban had lower rates of stroke, systemic embolism, major bleeding and reduced mortality compared to warfarin.

Original Publication:

N Engl J Med. 2011 Sep 15;365(11):981-92.

http://www.ncbi.nlm.nih.gov/pubmed/12466507

Eponym: Apixaban for Reduction In Stroke and Other ThromboemboLic Events in atrial fibrillation